Trial of droperidol as an antiemetic in cisplatin chemotherapy.
A trial of droperidol as an antiemetic was undertaken during 48 courses of cisplatin chemotherapy in 31 patients with cancer. The optimal loading dose was 10 mg iv, with a maintenance dose of 4 mg iv every 2 hours for four additional doses. Beyond this level, cardiovascular side effects became problematic.
S L
SL
Kelley
T J
TJ
Braun
T J
TJ
Meyer
P
P
Rempel
N W
NW
Pearlman
D000368:Aged; D000932:Antiemetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002945:Cisplatin / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004329:Droperidol / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000932:Antiemetics; D004329:Droperidol; D002945:Cisplatin